RNA, Messenger – Talk Bio

Moderna’s RSV Vaccines Face Safety Concerns Over Severe Infections in Infants

4 months ago talkbio0Tagged Advisory Committees, concerns, Infant, Moderna, Respiratory syncytial virus, RNA, Messenger, Safety, United States Food and Drug Administration, Vaccines

Moderna, RSV vaccines, safety concerns, severe infections, infants, mRNA vaccines, FDA, advisory committee

Mitigating Risks in mRNA Manufacturing: Strategies for Smooth Transition from Preclinical to Clinical Stages

6 months ago talkbio0Tagged analytical method, Automation, bony process, clinical transition, Control Groups, Materials, Preclinical, Quality, regulatory, Risk Management, RNA, Messenger

mRNA manufacturing, risk management, preclinical to clinical transition, quality control, regulatory compliance, raw material selection, process automation, analytical methods.

GSK Advances mRNA Flu Vaccine to Late-Stage Clinical Development Following Positive Phase II Results

7 months ago talkbio0Tagged Clinical Development, Effectiveness, Late stage, RNA, Messenger, Safety, SmithKline Beecham, Vaccines

GSK, mRNA flu vaccine, phase II results, late-stage clinical development, influenza A and B strains, vaccine efficacy, safety profile.

GSK Abandons HSV Vaccine Development After Phase 2 Failure, Paving Way for Moderna and BioNTech

7 months ago talkbio0Tagged BioNTech, HSV vaccine, Moderna, RNA, Messenger, Simplexvirus, SmithKline Beecham

GSK, HSV vaccine, phase 2 failure, Moderna, BioNTech, mRNA vaccines, herpes simplex virus

FDA Approves Updated COVID-19 Vaccines from Pfizer and Moderna for Enhanced Protection

8 months ago talkbio0Tagged Approved, authorization, COVID19 (disease), Emergency Situation, Guidelines, JN.1, KP.2, Lineage, Moderna, Pfizer, Pfizer/, RNA, Messenger, United States Food and Drug Administration, Vaccination, Vaccines, Variant

COVID-19 vaccines, FDA approval, mRNA vaccines, Pfizer, Moderna, updated vaccines, KP.2 variant, JN.1 lineage, emergency use authorization, vaccination guidelines.

GSK Partners with Flagship Pioneering to Develop 10 Novel Medicines and Vaccines

9 months ago talkbio0Tagged bioplatform companies, Drug Discovery, Flagship, Immunology, Partnership, Pfizer, Pioneering, Respiration Disorders, RNA, Messenger, SmithKline Beecham, Vaccines

GSK, Flagship Pioneering, drug discovery, vaccines, respiratory disease, immunology, bioplatform companies, mRNA vaccines, Pfizer, biotech partnership

Moderna Secures $176 Million BARDA Award for Bird Flu Vaccine Development

10 months ago talkbio0Tagged BARDA, development aspects, Influenza in Birds, Moderna, pandemic preparedness, RNA, Messenger, Vaccines

Moderna, BARDA, Bird Flu, Vaccine Development, mRNA Technology, Pandemic Preparedness

Exsilio Therapeutics Launches with $82 Million to Develop mRNA-Based Genomic Medicines Under Tal Zaks’ Leadership

10 months ago talkbio0Tagged Approved, Exsilio, Gene Modification, gene therapy, genomic medicines, Lipids, nanoparticle delivery, RNA, Messenger, safety profile, Tal Zaks

Exsilio Therapeutics, mRNA, genomic medicines, Tal Zaks, gene therapy, gene editing, lipid nanoparticle delivery, redosing, safety profile, gene therapy approval